Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.
You may also be interested in...
Annual Biopharma Fee Estimates Need More Transparency, BIO Says
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
Annual Biopharma Fee Estimates Need More Transparency, BIO Says
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
Schedule For Drug Fee Estimates Slips As IRS Revises Guidance
The Internal Revenue Service has pushed back some of the implementation deadlines for the new market-share based fees on drug manufacturers by a couple of weeks to accommodate issues raised in response to its November guidance.